PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced its participation in two upcoming investor conferences, ...

A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days ...

The U.S. IPO market seems to be cooling off this week, with no major listing planned. This week, Advanced Biomed ( ADVB) is ...

We have seen 187 institutional investors add shares of $BIO stock to their portfolio, and 249 decrease their positions in their most recent quarter. We have seen ...

Cryptocurrency custody firm BitGo is the latest digital asset firm to announce plans to hold an initial public offering (IPO) this year. BitGo plans to go public in coming months as sentiment ...

Prothena is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

In trading on Tuesday, shares of Bio-Rad Laboratories Inc (Symbol: BIO) crossed below their 200 day moving average of $320.76, changing hands as low as $320.44 per share. Bio-Rad Laboratories Inc ...

Fintel reports that on February 11, 2025, BMO Capital downgraded their outlook for Q32 Bio (LSE:0T6G) from Outperform to Market Perform. There are 173 funds or institutions reporting positions in ...

Apple (NASDAQ: AAPL) has been a public company for ... declared five stock splits since its 1980 initial public offering (IPO). The stock had several 2-for-1 splits between 1987 and 2005 (June ...

Tevogen Bio, a clinical-stage biotech company specializing in immunotherapy, recently met with the BARDA TechWatch team to discuss its ExacTcell technology, which aims to deliver affordable ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO CEO & Investor Conference taking place on February 10-11, 2025, in New York City. The company's management will present a ...

Sionna Therapeutics Inc. has opened on Nasdaq in the year’s fourth IPO, this one priced at the upper end of its original per-share range at $18. The cystic fibrosis therapy developer is looking for ...